美沙拉嗪缓释颗粒及柳氮磺吡啶治疗活动期轻、中度溃疡性结肠炎的疗效和不良反应比较  

Efficacy and side effects of the treatment of mild and moderate ulcerative colitis in the treatment of mild and moderate ulcerative colitis in the treatment of active and moderate ulcerative colitis

作　　者：高新英[1] 

机构地区：[1]泰安市中心医院,山东泰安271000

出　　处：《医疗装备》2016年第10期20-21,共2页Medical Equipment

摘　　要：目的比较美沙拉嗪缓释颗粒(艾迪莎)和柳氮磺吡啶治疗活动期轻、中度溃疡性结肠炎的临床疗效以及不良反应。方法选取66例溃疡性结肠炎患者,随机分为研究组与对照组,各33例。研究组给予美沙拉嗪缓释颗粒治疗;对照组患者则采用柳氮磺吡啶治疗,均连续治疗6周后,对比两组临床治疗效果以及不良反应发生率。结果治疗后,研究组治疗有效患者为32例,治疗总有效率为96.97%,对照组治疗有效患者29例,治疗总有效率为87.88%,两组对比差异有统计学意义(P<0.05)。结论采用美沙拉嗪缓释颗粒治疗轻、中度溃疡性结肠炎患者,临床疗效显著,不但能够有效提高临床治疗有效率,而且可以有效降低治疗期间不良反应的发生率。Objective To study the clinical ef icacy and adverse reactions of the Mesalazine particles and sustained release in the treatment of mild and moderate ulcerative colitis.Methods 66 patients with ulcerative colitis were randomly divided into study group and control group.The study group was treated with 6 weeks after treatment.The clinical ef icacy and adverse reactions of two groups were compared.Results After treatment, the study group of patients with ef ective treatment for 32 cases,the total ef ective rate was 96.97%,the control group of 29 patients with ef ective treatment,the total ef ective rate was 87.88%,the dif erence was statistical y significant （P 〈0.05）.Conclusion The clinical ef icacy of the treat-ment of mild and moderate ulcerative colitis with the Mesalazine and the sustained release granules is ef ective,not only can ef ectively improve the clinical treatment ef iciency,but also can ef ectively reduce the incidence of adverse reactions during treatment.

关 键 词：溃疡性结肠炎 美沙拉嗪缓释颗粒 柳氮磺吡啶 

分 类 号：R574.62[医药卫生—消化系统]